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Ewing Sarcoma (ES) is associated with a balanced chromosomal translocation that in
most cases leads to the expression of the oncogenic fusion protein and transcription fac-
tor EWS-FLI1. EWS-FLI1 has been shown to be crucial for ES cell survival and tumor
growth. However, its regulation is still enigmatic. To date, no functionally significant post-
translational modifications of EWS-FLI1 have been shown. Since ES are sensitive to histone
deacetylase inhibitors (HDI), and these inhibitors are advancing in clinical trials, we sought
to identify if EWS-FLI1 is directly acetylated. We convincingly show acetylation of the C-
terminal FLI1 (FLI1-CTD) domain, which is the DNA binding domain of EWS-FLI1. In vitro
acetylation studies showed that acetylated FLI1-CTD has higher DNA binding activity than
the non-acetylated protein. Over-expression of PCAF or treatment with HDI increased the
transcriptional activity of EWS-FLI1, when co-expressed in Cos7 cells. However, our data
that evaluates the acetylation of full-length EWS-FLI1 in ES cells remains unclear, despite
creating acetylation specific antibodies to four potential acetylation sites.We conclude that
EWS-FLI1 may either gain access to chromatin as a result of histone acetylation or undergo
regulation by direct acetylation.These data should be considered when patients are treated
with HDAC inhibitors. Further investigation of this phenomenon will reveal if this potential
acetylation has an impact on tumor response.
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INTRODUCTION
Ewing sarcoma (ES) is the second most frequent primary bone
tumor of childhood and early adolescence. It is associated with spe-
cific chromosomal translocations, resulting in an in-frame fusion
of the 5′ transactivation domain of EWS to the 3′ DNA binding
domain of an ETS family transcription factor. FLI1, ERG, ETV1,
ETV4, and FEV have all been described as fusion partners for EWS
in ES (Khoury, 2005). The EWS-ETS fusion is considered causative
in the development of ESs since the aberrant transcription factors
deregulate the cellular gene expression program (Hancock and
Lessnick, 2008). Patients with ES require new therapy that both
decreases mortality and reduces long term morbidity (Esiashvili
et al., 2008). EWS-ets are recognized therapeutic targets, yet little
is known about their post-translational regulation.
During the past decade, acetylation has emerged as a key
mechanism for post-translational regulation of both histones and
transcription factors like NF-kB, p53, GATA, and many others
(Spange et al., 2009). Acetylation is a reversible modification, in
which histone acetyltransferases (HAT) transfer the acetyl moi-
ety from acetyl-CoA to the ε-amino groups of lysine residues and
is reversed by histone deacetylases. Acetylation by nuclear A-type
HATs is directly linked to transcription regulation (Spange et al.,
Abbreviations: comp, competitor; ES, Ewing sarcoma; HAT, histone acetyltrans-
ferase; HDAC, histone deacetylase; HDI, histone deacetylase inhibitor(s); MS, mass
spectrometry; SAHA, suberoylanilide hydroxamic acid, also known as vorinostat,
marketed as Zolinza; TSA, trichostatin A.
2009) and are subdivided into five families: GNAT (Gcn5-related),
MYST (e.g., TIP60), p300/CBP, basal/general transcription fac-
tors, and nuclear receptor co-factors. They do not acetylate lysine
moieties randomly but instead often use the motif GKxxP, where
the acetylated lysine is preceded by a glycine. New sites are being
rapidly discovered (Choudhary et al., 2009; Smith and Workman,
2009) showing that this motif has serious limitations in predict-
ing non-histone protein acetylation. Numerous HATs further-
more undergo functionally relevant auto-acetylation (Thompson
et al., 2004). The consequences of acetylation include alterations
in protein stability, protein–protein interaction, DNA binding,
and transcription activation. Histone deacetylase inhibitors (HDI)
are advancing in clinical trials (Tan et al., 2010); thus enhanced
knowledge of the effects of acetylation can inform therapeutic
trials.
Little is known about post-translational modification of the
EWS-FLI1 fusion protein, and there are no reports describing
lysine acetylation (Klevernic et al., 2009). EWS-FLI1, EWS-ER81,
and EWS-ATF form complexes with the acetyltransferases p300
(Fuchs et al., 2003) and CBP (Fujimura et al., 2001; Araya et al.,
2003) leading to transcriptional activation. When EWS-FLI1 inter-
acts with p300 alterations in histone acetylation are observed
(Nakatani et al., 2003). When ES cells are treated with HDI, EWS-
FLI1 protein and mRNA levels decrease, however acetylation of
EWS-FLI1 was not reported (Sakimura et al., 2005). Studies with
the HDI MS-275 showed an average IC50 in the nanomolar range
(100 nM to 1µM) in ES cells accompanied by de-repression of the
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EWS-FLI1 target TGFβRII, re-expression of the histone acetyla-
tion sensitive locus p21 and a dose-dependent decrease in tumor
volume in MS-275-treated mice (Jaboin et al., 2002). The HDI
vorinostat recently completed Phase I testing for childhood cancer
(Fouladi et al., 2010).
The therapeutic utility of HDI would increase dramatically
if critical acetylation targets were identified. We provide evi-
dence that the co-expression of EWS-FLI1 with histone acetylases
increases EWS-FLI1 transcriptional activity based upon increased
binding to DNA. The C-terminal region of EWS-FLI1 was fully
characterized in vitro, for acetylation marks. However, the ability
to identify these marks on full-length EWS-FLI1 either in vitro or
in cell based assays was not successful. These data provide a mech-
anistic insight into EWS-FLI1 function which may potentially lead
to pharmacodynamic models of inhibitor activity.
EXPERIMENTAL PROCEDURES
CELL CULTURE
Ewing sarcoma cells (A4573, EWS-FLI1 type III; SKES-1, EWS-
FLI1 type II; TC32 and TC71, EWS-FLI1 type I) were maintained
in RPMI, 10% FBS under standard cell culture conditions. Cos7
cells were maintained in DMEM, 10% FBS. HDI treatment was
carried out with 2µM suberoylanilide hydroxamic acid (SAHA,
also known as vorinostat) or 0.3µM Trichostatin A (TSA) for 8
and 16 h, respectively.
WESTERN BLOTTING, ANTIBODIES
Western blots were carried out as previously described
(Beauchamp et al., 2009). Antibodies used are: α-HA-Tag
(6E2, Cell Signaling); α-Flag and α-Flag beads (Sigma); a-
acetyl-Lysine [Upstate, 4G12, 06-933 (mouse); Stressgen, KAP-
TF120 (rabbit)], α-FLI1 (C-19, sc-356), α-PCAF (E-8, sc-
13124), α-CBP (A-22, sc-369), α-p300 (N-15, sc-584) all
from Santa Cruz; α-PARP (C2-10; Trevigen). Acetylation site-
specific acetyl-EWS-FLI1 antibodies using the following pep-
tides: K240Ac (NH2−) CMNSGLN(K-Ac)SPPLGG (−CONH2),
K252Ac (NH2−) CGAQTIS (K-Ac)NTEQRP (−CONH2),
K380Ac (NH2−) CTESSMY(K-Ac)YPSDIS (CONH2), K397Ac
(NH2−)CYHAHQQ(K-Ac)VNFVPP (CONH2) were made in
cooperation with Innovagen (Sweden). Their specificity was tested
as shown in Figure 6 by competition experiments using acetylated
peptides.
TRANSFECTION, DNA CONSTRUCTS, AND IMMUNOPRECIPITATION
Cos7 cells were transfected using Fugene6 (Roche), ES cells
were electroporated with the Cellporator (Life technologies).
DNA constructs used are pCINeo-EWS-FLI1 pcDNA4TO-PCAF,
pcDNA4TO-PCAF∆HAT, and p300-CHA as well as the corre-
sponding empty vectors. For reporter assays the EWS-FLI1 respon-
sive NR0B1 microsatellite luciferase construct was used, kindly
provided by Dr. Steven Lessnick (University of Utah; Gangwal
et al., 2008). Generally cells were lysed ∼30 h post transfection.
Immunoprecipitations were carried out for 4 h at 4˚C using Protein
G agarose beads (Invitrogen).
REPORTER ASSAY
For reporter assays Cos7 cells were plated the day before trans-
fection and transfected in triplicates. Cells were lysed in passive
lysis buffer (Promega) 30–36 h post transfection and subjected
to luciferase measurement using Dual-Luciferase-Reporter Assay
System (Promega). Treatment of reporter assays with 0.3µM TSA
or 2µM SAHA was carried out for 8 h prior to cell harvest.
INCLUSION BODY AND PROTEIN PURIFICATION
Recombinant proteins were expressed as 6×His tagged proteins
in BL21 bacteria. Inclusion bodies were isolated using BugBuster
protein extraction reagent (Novagen) according to the manufac-
turer’s protocol. Inclusion bodies were subsequently solubilized in
binding buffer (see below), filtered (0.2µm), and subjected to col-
umn purification (1 ml HiTrap purification columns, ActaPrime
system, Amersham) using a refolding method recommended by
the manufacturer with the following buffers: refolding buffer
(20 mM Tris pH 8, 0.5 M NaCl, 5 mM imidazole), solubilization
buffer (refolding buffer plus 8 M urea), binding buffer (refolding
buffer plus 6 M guanidine hydrochloride), elution buffer (refold-
ing buffer plus 2 M imidazole). Purified FLI1-C-terminal protein
domain (FLI-CTD) was dialyzed (20 mM Tris pH 8.0, 20% glyc-
erol, 100 mM KCl, 0.2 mM EDTA, 1 mM DTT), aliquoted and
stored at−80˚C. EWS-FLI1 preparations were used as eluted; due
to its N-terminal disordered EWS-portion the physical properties
of EWS-FLI1 cannot undergo either dialyzing or freezing.
IN VITRO ACETYLATION
An in vitro acetylation reaction with recombinant FLI-CTD con-
tained 50 mM Tris-HCl, pH 8.0, 10% glycerol, 0.1 mM EDTA,
1 mM DTT, 5 mM sodium butyrate, 120 nCi of [14C]-acetyl-CoA
(55 mci/mmol, Amersham), up to 10µg of purified substrate pro-
tein, and 1.25µg of recombinant CBP (HAT domain, Biomol) or
baculovirus expressed PCAF. Samples were incubated at 30˚C for
90 min, and then subjected to SDS PAGE. Gels were fixed, rinsed
in enhancer solution, dried, and subjected to autoradiography
using Kodak BioMax MS films. For mass spectrometric analysis
and EMSA experiments 45µl non-radioactive acetylation reac-
tions were carried out with up to 30µg recombinant substrate
protein, 1.1 mM Acetyl-CoA (tri-lithium salt, Roche), and 6.5µg
CBP/p300 at 30˚C for 90 min. Successful acetylation was verified
by western blot analysis using an acetyl-lysine specific antibody
(Stressgen). In vitro acetylations with the full-length EWS-FLI1
were carried out with smaller protein amounts (∼2µg) and higher
reaction volumes so that the imidazole concentration in the reac-
tion was diluted to <100 mM. Background was subtracted from
all signals [as determined with the Multigauge software (Fuji), Q-
B/pixel2], then the negative control (samples without enzyme) for
each individual substrate was subtracted to give rise to the shown
delta (Q-B/pixel2) values.
NON-RADIOACTIVE EMSA
For non-radioactive gel-shift assays 1µg recombinant protein
was incubated with 500 fmol of biotin labeled double-stranded
oligonucleotides containing the consensus ets-binding site GGAA
as previously described (Uren et al., 2004). Complexes were sep-
arated on a 6% gel retardation gel (Invitrogen) in 0.5× TBE, and
subsequently transferred on Zeta GT (Biorad) membrane. Dried
membranes were UV cross-linked for 15 min and subsequently
blocked with 10× blocking solution (3.65 g NaCl, 1.2 g Na2HPO4,
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FIGURE 1 | Acetylases increase transcriptional and DNA binding activity
of EWS-FLI1. (A) The EWS-FLI1 responsive NR0B1 promoter (Gangwal et al.,
2008) and pCI-EWS-FLI1 were co-transfected into Cos7 cells without PCAF
nor p300 (white bar) or with increasing amounts of either PCAF or p300 (gray
bars) or a mutant HAT construct lacking the histone acetyltransferase domain
(PCAF ∆HAT, black bar). Twenty-four hours later promoter derived luciferase
activity as well as protein levels were analyzed. Bar graphs result from
triplicate transfection and duplicate luciferase measurement. EWS-FLI1 levels
did not exhibit any patterns of change across multiple experiments and those
changes here were not representative and thus not considered in final
conclusions.
(Continued)
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FIGURE 1 | Continued
(B) In vitro acetylation was carried out as described and samples of the
reaction were tested for successful acetylation by western blot using an
anti-acetyl-lysine antibody. (C) Recombinant, refolded FLI1-CTD
specifically binds to the ets-binding site of dsDNA. The specificity of the
FLI1-CTD for the ets-binding site in the oligonucleotide was proven by the
lack of binding to mutant oligonucleotide (lane 8), by the competition of
unlabeled wild type oligonucleotide (lanes 2–4), and by the lack of
competition with mutant oligonucleotide (lanes 5–7); comp, competitor;
bio, biotinylated. (D) Samples were subjected to non-radioactive EMSA
using biotin labeled ets binding site as a probe. Unlabeled wild type
competitor was used at 1, 2.5, 5, 10, and 50 times excess. Mutant
competitor was only used at the highest concentration (50 times excess).
(E) Aliquots of the reactions were tested for equal loading by Coomassie
staining. (F) Densitometric analysis of (B,C). Relative binding=EMSA
signal/Coomassie signal.
0.5 g NaH2PO4, 25 g SDS, dH2O to 0.5 L) for 10 min. The biotin
labeled probe was detected with horseradish peroxidase labeled
streptavidin in a FujiFilm LAS3000 image analyzer.
MASS SPECTROMETRY
Trypsin generated peptides of in vitro acetylation reactions were
analyzed using ESI LC MS/MS (QStarELITE/TEMPO MDLC sys-
tem) mass spectrometry (MS) using the software Protein Pilot
V3.0 and the UniProt database.
RESULTS
EWS-FLI1 MEDIATED TRANSCRIPTION INCREASES WITH ACETYLATION
Since HDI are potential adjuvant treatment options for patients
with pediatric sarcoma, our goal was to evaluate the effects of
acetylation upon EWS-FLI1 as a therapeutic target. First we
investigated whether HAT coactivate EWS-FLI1 mediated tran-
scription. The EWS-FLI1 responsive reporter construct (NR0B1,
Gangwal et al., 2008) and an EWS-FLI1 expression construct
were transfected into Cos7 cells, along with increasing amounts
of a PCAF expression construct (Figure 1A). PCAF enhanced
the EWS-FLI1 mediated activation of the luciferase reporter in
a concentration dependent manner. However, in the absence of
EWS-FLI1, PCAF did not alter the promoter activity. To further
support the role of acetylation as a potential cause of the increased
activity, a HAT deletion mutant (∆HAT) of PCAF was used; this
acetylase deficient PCAF did not increase the EWS-FLI1 driven
reporter activity (Figure 1A, left panel).
In a similar manner as PCAF, expression of p300 along
with EWS-FLI1 increased transcription of the NR0B1 promoter
(Figure 1A, right panel). Overall, we measured dose-dependent
increases in EWS-FLI1 transcriptional activity upon the expression
of either HAT. Since the reporter construct lacks histone wrapping,
this result was followed by experiments to evaluate whether the
increased promoter activity could be due to enhanced EWS-FLI1
binding to DNA secondary to acetylation.
ACETYLATION INCREASES DNA BINDING
EWS-FLI1 DNA binding is well characterized and occurs through-
out the ets family DNA binding domain of FLI1. For non-
radioactive DNA binding assays and MS following in vitro acetyla-
tion reactions big scale purified full-length EWS-FLI1 preparations
were needed. However, this kind of purification in appropriate
buffers for acetylation was challenging. Since most of the acetylat-
able lysine residues are contained in the FLI1 C-terminal domain
(CTD),we used this domain in DNA binding studies. We measured
FLI1-CTD DNA binding using an electrophoretic mobility shift
assay (EMSA). FLIl-CTD was acetylated by the enzymatic domain
of CBP (CBP-HAT, Figure 1B). An ets binding site oligonucleotide
with unlabeled competitor along with mutant sequences were used
to assess binding of the FLI1-CTD, followed by quantification of
band density (Uren et al., 2004). We evaluated the specificity of
the binding using mutant and cold competition (Figure 1C). The
acetylated FLI1-CTD demonstrated a four-fold increase in bind-
ing compared with non-acetylated control protein (Figures 1D,F,
compare column 1 and 9). When titrating in the cold wild-type
competitor, a consistent enhancement of acetyl-FLI-CTD binding
was measured. Even when 50-fold excess of a mutant competitor
was used (matching the highest concentration of the wild-type
competitor) the acetyl-FLI-CTD binding was twice as high as the
non-acetylated protein (Figures 1D,F, lanes 7 and 15). All gel-shift
lanes had equal amounts of protein (Figure 1E). This data shows
enhanced DNA binding of acetylated FLI1-CTD which led us to
investigate which of the known acetylases might be responsible for
EWS-FLI1 acetylation.
P300 AND PCAF CAN BOTH ACETYLATE RECOMBINANT EWS-FLI1
We evaluated each of the three major acetyltransferases indepen-
dently for their ability to directly acetylate recombinant proteins:
full-length EWS-FLI1 (type I 55.4 kDa, 13 lysines), full-length
FLI1 (50.9 kDa, 24 lysines), full-length EWS (68.5 kDa, 18 lysines),
and the C-terminal FLI1 domain (FLI-CTD, 24 kDa, 12 lysines)
were used as substrate. We used full-length p300, PCAF, and the
CBP-HAT domain for in vitro acetylation assays.
Full-length wild-type FLI1 as well as the FLI1-CTD were
strongly acetylated by all three HATs (Figures 2A–C, lanes 1–4).
EWS-FLI1 type I was acetylated, but to a lesser degree than FLI1,
by both p300 and PCAF, while CBP failed to acetylate the fusion
protein (Figure 2, lanes 5 and 6). Full-length EWS was acetylated
by both CBP and PCAF while p300 failed to acetylate it (Figure 2,
lanes 7 and 8). We addressed the possibility that the non-enzymatic
background acetylation of EWS-FLI1 (Figure 2, lanes 5 compared
to 6) might result from an unknown acetyltransferase activity of
EWS-FLI1 itself. However, our experiments confirmed that EWS-
FLI1 has no such enzymatic activity (data not shown). We used
densitometric quantification of the band intensity to compare the
lanes with the HAT present relative to its absence for each of the
different enzymes (Figure 2D).
SPECIFIC LYSINE RESIDUES ARE IDENTIFIED AS THE FLI1-CTD
ACETYLATION SITES BY MASS SPECTROSCOPY
We sought to identify individual acetylated residues within EWS-
FLI1 by means of MS analysis. Twelve of 13 lysine residues of
EWS-FLI1 are located in the FLI-CTD (Figure 3A), while the
N-terminal EWS-domain attributes only one lysine. Isobaric inter-
ference can lead to false assignment of modifications to peptides
as acetylation and trimethylation both generate the same+42 kDa
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FIGURE 2 | Full-length EWS-FLI1, and its C-terminal FLI1 domain
(FLI1-CTD) become acetylated in vitro by p300/CBP and PCAF.
Recombinant, refolded full-length FLI1 (ERG B), FLI-CTD, EWS-FLI1, and
EWS were subjected to in vitro acetylation (C14-AcetylCoA), PAGE, and
autoradiography using p300 (A), PCAF (B), and CBP (C). Autoacetylation of
the acetyltransferases serves as internal positive control. (D) Densitometric
analysis of the band intensities shown in A–C using the densitometric
values/area (Q/pixel2). These acetylations were replications were: the full
length EWS and FLI1, EWS-FLI1 each performed twice, the FLI-CTD
greater than 10 replicates.
mass shift. However, Zhang et al. (2004) demonstrated that a lysine
in a peptide modified by methylation or acetylation can be differ-
entiated by MS despite isobaric interference when all of the three
following mass spectrometric parameters are used: (1) the acetyl-
group characteristic+42 Da mass shift of the b- and y-ion signals
of the lysine residues in question, (2) a specific acetyl-lysine marker
ion atm/z 126.09 (126.1), and (3) the acetyl-lysine immonium ion
at m/z 143.1.
We repeatedly detected CBP-dependent acetylation of the lysine
residues at positions 240, 252, and 380 (numbering refers to the
full-length FLI1 protein, see Figure 3B for amino acid positions
in the EWS-FLI1 fusion proteins). Exemplary peptides of the
detected acetylation sites are shown in Figure 3C. The same pep-
tides were obtained from non-acetylated and acetylated samples.
However, acetylation specific leader ions at 126.09 were detected
only in acetylated peptides. Acetylation of lysines K334, K345,
K350, and K397 were detected occasionally with CBP (data not
shown). Since the ets domain contains an accumulation of lysine
residues (which all represent trypsin cleavage sites) most of the
generated peptides of the ets domain are too small for efficient
resolution by MS. As a result, the DNA binding domain was
not well covered by the trypsin generated peptides (77% cover-
age, data not shown). Therefore, to evaluate acetylation in this
region we also generated peptides using the endopeptidase Lys-
C (data not shown). Lys-C cleaves at lysine residues but omits
the site when the lysine residue is acetylated. Lys-C digestion did
not increase the detection of additional DNA binding domain
peptides, supportive of the conclusion that Lys residues in the
DNA binding domain are not acetylated. As shown above the
homolog p300 seemed to be more active in acetylating EWS-FLI1
than CBP. Therefore, we confirmed the MS analysis of the CTD
using p300 and detected a similar acetylation pattern (K240 and
K252, Figure 3C). In addition we carried out MS analysis with
PCAF and obtained acetylation at the same position K240 (data
not shown).
K240, K252, AND K380 ARE VALIDATED AS ACETYLATION SITES
The ets family of proteins shows modest conservation of lysine,
or related glutamine at residues we identified in the MS analysis
(Figures 4A,B). We validated the acetylation residues by creating
lysine (K) to arginine (R) mutations. These amino acid substitu-
tions are known to cause relatively conserved structural changes
but prevent acetylation. K4bR is a FLI-CTD protein that has the
four lysine residues 240, 252, 380, and 397 mutated to arginine
(Figure 4A). These lysine residues are located outside the ets
domain. Lysine 397, while not specifically detected by MS analy-
sis, was included because it contributed to the effect of K380
acetylation in full-length FLI1 (Asano et al., 2007). The mutant
K9aR has 9 out of 12 lysines in the FLI1-CTD mutated to argi-
nine, which includes the ets domain lysines 325, 327, 334, 345,
350, 354, 359 (except 310), and the two lysines 380 and 397 out-
side the ets domain (refer to Figures 3A and 4A for positions).
K4bR showed abolished CBP as well as PCAF mediated acetyla-
tion, however K9aR (with K240 and K252) had a small amount
of residual acetylation (Figures 4C,D). We also mutated indi-
vidual acetylation sites and paired lysine positions. While single
mutants did not have an effect on the overall acetylation sig-
nal (data not shown), subsequent in vitro acetylation studies
showed reduced CBP acetylation kinetics of the double mutant
K380, 397R (Figures 4E,F). This kinetic assay confirmed that
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FIGURE 3 | Identification of individual acetylation sites in FLI1-CTD
by mass spectrometry. (A) Sequence of the C-terminal FLI1 domain
(FLI1-CTD) as present in all EWS-FLI1 fusion types. Top numbers (BOLD)
correspond to amino acid positions in the wild type FLI1 protein; lower
numbers refer to positions in the EWS-FLI1 (type I) fusion protein. Lysine
residues identified as being acetylated are marked in red and their
numbering corresponds to the wild type FLI1 sequence. The ets-domain
is boxed in yellow. (B) Lysine positions in the full-length wild type FLI1
and the corresponding lysine positions in the three different EWS-FLI1
fusion proteins. (C) Results of MS analysis of in vitro acetylated
FLI1-CTD protein. Recombinant, refolded FLI-CTD was subjected to
in vitro acetylation by CBP and p300 (no enzyme as control). Trypsin
generated peptides were analyzed using ESI LC MS/MS
(QStarELITE/TEMPO MDLC system) MS as described in the Section
“Experimental Procedures.” The lysine positions most abundantly found
as being acetylated are listed.
the K4bR mutant was unable to be acetylated. Similarly, PCAF
acetylation of the double mutant was reduced (data not shown).
Thus, we concluded that K240, K252, and K380 represent the
three main acetylation sites of the C-terminal FLI1 domain of
the fusion protein, with K397 potentially serving a cooperative
function.
The DNA binding ability of a protein depends on the structural
integrity of its DNA binding domain. EMSA with the K4bR and
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FIGURE 4 | Mutagenesis confirms K240, K252, and K380 as major
acetylation sites. (A) Two lysine to arginine mutants were created of
the FLI1-CTD of EWS-FLI1 using site directed mutagenesis. K4bR
(K240,252,380,397R) and K9aR (K325,327,334,345,350,354,359,380,
397R). (B) Protein sequence alignment of different ets family members
at relevant lysine positions. Protein sequences of ETS1 (P14921), ETS2
(P15036), ETV6 (P41212), ETV7 (Q9Y603), SPIB (Q01892), SPI1
(P17947), ETV1 (P50549), ETV5 (P41161), ETV4 (P43268), ERG (P11308),
FLI1 (Q01543), FEV (Q99581), and ETV2 (O00321) were aligned using
UniProt, to reveal conservation of Lysine positions K240, K252, K380,
and K397. (C,D) Acetylation mutants were in vitro acetylated by CBP (C)
or PCAF (D). (E) Kinetic of CBP in vitro acetylation of K4bR and K380,
397R double mutant proteins. (F) Densitometric analysis of (E) (wt,
filled squares; K4bR, open triangles; K380,397R double mutant, open
circles). For in vitro acetylations dried gels were re-hydrated after
exposure and stained for Coomassie to show equal loading [lower
panels (B–D,F)]. This experiment was performed only once in this
kinetic fashion. (G) Non-radioactive EMSA using ets-binding site
containing oligonucleotides and mutant recombinant proteins. Fractions
of the EMSA samples were analyzed by Coomassie (lower panel). (H)
Densitometric analysis of images shown in (G). Relative
binding=EMSA signal/Coomassie signal.
K9aR proteins were performed in order to determine if the mul-
tiple mutations would disrupt DNA binding. The mutant K9aR
lost its ability to bind to an ets-binding site containing oligonu-
cleotide in a non-radioactive EMSA, while K4bR retained similar
DNA binding to that of the non-acetylated wild-type protein
(Figures 4G,H). The K4bR mutant, at baseline, has approximately
the same DNA binding activity as the non-acetylated wild-type
protein when controlled for the amount of protein in the assay
(Figure 4H). This implies that in K4bR structural integrity is
maintained, in contrast to the mutant K9aR.
ES CELLS EXPRESS HISTONE ACETYLTRANSFERASES
Histone acetyltransferases are important co-factors for transcrip-
tion; as such they are also implicated in the transcription of
oncogenic and tumor suppressing transcription factors [e.g., c-
myc (Patel et al., 2004) and p53 (Di Stefano et al., 2005)]. To
investigate the potential biological importance of different HATs
in ES cells we first determined which HATs are expressed in ES
cells (Figure 5A). We determined that all seven ES cell lines tested
expressed both p300 and CBP. Intriguingly, PCAF was expressed
by all type I and type III EWS-FLI1 expressing cell lines, while
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EWS-FLI1 type II cell lines, SKES-1 and RDES, only weakly express
PCAF. While we were not able to detect acetylated EWS-FLI1 in
total cell lysate, when EWS-FLI1 was enriched by immunopre-
cipitation from A4573 cell lysate, we observed that EWS-FLI1
type III is acetylated intracellular using a general acetyl-lysine
antibody (Figure 5B). Since this was a pan-acetyl-lysine anti-
body, we therefore assumed that the detection of acetyl EWS-FLI1
was reduced due to low antibody affinity. Therefore we gen-
erated novel acetyl-EWS-FLI1 specific antibodies for following
applications.
P300 AND PCAF FORM A COMPLEX WITH EWS-FLI1
Since ES cells express all major HATs, interactions between
EWS-FLI1 and the different HATs were investigated. Immuno-
precipitation experiments with purified recombinant EWS-FLI1
and p300 PCAF proteins demonstrated that EWS-FLI1 com-
plexes with both HATs (Figure 5C). In cell based experiments,
we showed that endogenous EWS-FLI1 was only able to co-
precipitate PCAF when it was exogenously expressed in TC32
cells (Figure 5D). When endogenous EWS-FLI1 was immuno-
precipitated from TC32, no acetylation was detectable. However,
when TC32 cells were either co-transfected with PCAF or treated
with the HDI TSA, EWS-FLI1 acetylation could be detected in
immunoprecipitated protein using a pool of acetyl-EWS-FLI1
specific antibodies (Figure 5E). These acetylation specific anti-
bodies are novel reagents that were prepared by immunizing
rabbits with acetylated peptides (see Experimental Procedures).
Specificity of these antibodies was confirmed with competition
studies using acetylated peptide (Figure 6). Thus, acetylated EWS-
FLI1 should be detectable in ES cells with appropriately sensitive
reagents.
SITE-SPECIFIC ANTIBODIES CONFIRM INTRACELLULAR ACETYLATION
LEADING TO ENHANCED EWS-FLI1 TRANSCRIPTION
EWS-FLI1 (type 1), and PCAF were co-transfected into Cos7
cells and this complex was confirmed by co-immunoprecipitation
(Figure 7A). Acetylation was barely detectable under basal
conditions of expressed EWS-FLI1. However, when cells were
co-transfected with PCAF and treated with TSA, acetylation
increased. The combination of TSA treatment and PCAF expres-
sion significantly enhanced our ability to observe EWS-FLI1 acety-
lation at residues K240 and K380 with site-specific antibodies
(Figure 7B). In contrast, the full-length EF-K4bR mutant was not
acetylated with basal expression, nor could it be acetylated with
optimal acetylation conditions using expressed PCAF and TSA
treatment (Figure 7C). Therefore, we used the EF-K4bR mutant
(K240,252,380,397R) to evaluate transcriptional activation. Wild-
type EWS-FLI1 was transfected into Cos7 cells and treatment with
either SAHA or TSA increased transcriptional activity (Figure 7D,
comparing lanes 8 or 9 to lane 7).
PCAF expression also increased EWS-FLI1 transcriptional
activity (Figure 7D, comparing lanes 10–7). The EF-K4bR mutant
had slightly less activity than wild-type EF, however unlike the
wild-type protein, the luciferase activity did not significantly
increase with either SAHA or TSA (Figure 7D comparing lanes
14 or 15 to lane 13). When the EF-K4bR mutant was co-expressed
with PCAF, promoter activity increased, and like wild-type EF,
no additional increase was seen with the HDI. Although less
active than EWS-FLI1, the EF-K4bR was still responsive to PCAF
stimulation, but it was insensitive to treatment with HDIs. This
supports a role for these acetylation sites in EWS-FLI1 activated
transcription. That PCAF also increased promoter activity even
when EWS-FLI1 cannot be acetylated at the four lysine sites (240,
252, 380, 397) points to additional PCAF acetylation sites within
the protein.
DISCUSSION
The direct functional modulation of transcription factors by acety-
lation is an area of significant research. Our initial hypothesis
asked whether EWS-FLI1 activity was modulated by acetylation.
We showed that co-expression of PCAF or p300 increased the
promoter activation by EWS-FLI1. Following this, we determined
that acetylation of the FLI-CTD increased DNA binding affin-
ity, as one explanation of this increased promoter activity. We
then sought to identify the specific residues of EWS-FLI1 that
are acetylated, first using in vitro acetylation reactions followed
by MS. The FLI-CTD fragment led us to identify K240, K252,
and K380 as probable sites for acetylation. Mutagenesis followed
by acetylation assays confirmed these sites. We then showed that
ES cells expressed and EWS-FLI1 bound to the various acety-
lases, but required exogenous expression for this co-precipitation.
Finally we confirmed K240 and K380 as sites of acetylation in co-
transfected COS cells and that acetylation at these sites increased
EWS-FLI1 driven promoter activation. Overall, our data supports
a role for acetylation in EWS-FLI1 mediated transcriptional reg-
ulation. However, challenges in identifying an acetylation mark
upon full-length EWS-FLI1 using in vitro acetylation along with
an absence of detectable acetylation in ES cells prevents a clear
acceptance of our hypothesis.
Transcription factors belonging to the ets family are regulated
by acetylation (Goel and Janknecht, 2003; Bai et al., 2005). Pu.1 is
a substrate for p300 with the three major acetylation sites residing
within the ets domain. The transcriptional activity of Pu.1 was
increased by p300 interaction as well as treatment with the HDI,
TSA (Bai et al., 2005). ER81 interacts with, and is a substrate for,
both p300 and PCAF. In contrast to Pu.1 acetylation takes place
outside the ets domain at the N-terminal of Pu.1. However, both
HATs also increase transcriptional activation and DNA binding of
ER81 (Goel and Janknecht, 2003). Wild-type FLI1 is acetylated by
PCAF upon stimulation with TGFβ in dermal fibroblasts (Asano
et al., 2007). The acetylation of FLI1 at lysine 380 abrogates the
repressor function of Fli1 and shortens its half-life, thus reducing
its DNA binding and transcriptional activity.
We have identified multiple relevant acetylation sites in the
C-terminal FLI1 domain of the fusion protein including lysine
residues K240, K252, and K380 (referring to the positioning within
the wt FLI1 protein). This conclusion is based upon a combination
of MS, mutagenesis and novel site-specific acetylation antibodies.
Our experimental results are in agreement with observations for
the ETS proteins Pu.1 and ER81. An increase of transcription and
DNA binding upon co-expression of HATs has been observed for
both proteins in response to HDI treatment (Goel and Janknecht,
2003; Bai et al., 2005). Additionally ER81 becomes stabilized upon
acetylation.
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FIGURE 5 | Histone acetyltransferases are expressed in ES cells and
directly interact with EWS-FLI1. (A) Whole cell lysates of various ES cells
were tested for expression of CBP, p300, and PCAF protein by western blot.
(B) EWS-FLI1 was immunoprecipitated from A4573 cells with a FLI1 antibody
to detect acetylation by western blot using a pan-α-acetyl lysine. (C)
Recombinant EWS-FLI1 directly binds to recombinant p300 (upper panel) and
recombinant PCAF (lower panel). One microgram of each recombinant protein
was used. (D) TC32 cells were transfected with PCAF expression plasmid.
After 24 h lysates were subjected to immunoprecipitation with FLI1 antibody
to show that the EWS-FLI1 PCAF complex also occurs in ES cells. (E) TC32
cells were transfected with PCAF followed by treatment with 0.3µM TSA for
16 h. Whole cell lysates were immunoprecipitated with an anti-FLI1 antibody.
A pool of site-specific anti-acetyl-EWS-FLI1 antibodies was used to detect
acetyl-EWS-FLI1 (antibodies to K240Ac, K252Ac, K380Ac, K397Ac. For
antibody generation, refer to see Experimental Procedures). The same
membrane was stripped and reprobed with α-FLI1 and α-actin.
The key question is why these acetylation marks are not
observed in ES cell lines. In our experiments, detection of
acetylated EWS-FLI1 required significant amplification through
either protein over-expression or drug treatment. Thus, our
findings pose the question: is EWS-FLI1 actually regulated by
acetylation and if so, why is acetylated EWS-FLI1 not more
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abundant? One possibility is that the full-length fusion protein
alters the ability of acetylases to bind and in fact, EWS-FLI1, unlike
wild-type FLI1, may not be regulated by acetylation. Since EWS-
FLI1 is an intrinsically disordered protein, its solvent exposure in
cells, thus its exposure to enzymatic alteration is likely different
from one of its domains (Erkizan et al., 2010). This escape from
regulation may be another manifestation that leads to oncogenesis.
An alternative explanation considers that most cells do not tol-
erate (over-) expression of exogenous EWS-FLI1 (Tanaka et al.,
1997). Situations that are permissive of EWS-FLI1 expression
include secondary mutations in growth and cell cycle controlling
genes like p53 or p16 (e.g., Deneen and Denny, 2001). Acetylation
increases transcription and DNA binding of EWS-FLI1, therefore,
the additional potency might subdue the cells. It is however also
possible that the inability to clearly detect acetylation of full-length
EWS-FL1 is due to the limited sensitivity of the specific antibodies
directed against acetylated forms of the protein. For example, in
the case of many other proteins, including p53, it has been histor-
ically difficult to accurately estimate the ratio between acetylated
and non-acetylated forms.
The balance of the effects of EWS-FLI1 acetylation, in contrast
to the general effects HDI have upon ES cells is experimentally
challenging. The acetylation of EWS-FLI1 under native conditions
is low, but present, as shown by novel acetyl-specific antibodies.
The importance of the single sites and their biologic significance
remains cryptic despite the increase of acetylation at all four indi-
vidual lysines by PCAF. Similar to the oncogenes p53 and c-Myc
the sites might have different relevance for a differential regulation
of EWS-FLI1. P53 is acetylated at two different sites which differ-
entially regulate its binding to DNA and its ability to induce an
apoptotic response in lung carcinoma cells (Knights et al., 2006).
c-Myc, is differentially regulated by hGCN5/PCAF (Patel et al.,
2004), and p300/CBP (Faiola et al., 2005), resulting in altered
protein stability (Faiola et al., 2005).
Acetylation of K380 and K397 decrease the stability of full-
length wild-type FLI1, resulting in FLI1 protein degradation
(Asano et al., 2007). We had initially hypothesized acetylation
of EWS-FLI1 might be relevant for its protein stability as well,
similar to previous publications (Sakimura et al., 2005), yet mul-
tiple repeated experiments did not demonstrate altered stability
upon increased acetylation. Our specific experiments addressing
EWS-FLI1 half-life were confounded by ES cell sensitivity to agents
like cycloheximide or proteasomal inhibitors, traditionally used to
block de novo-protein synthesis or protein degradation, did not
allow for the necessary incubation times to complete experiments
addressing protein stability.
An increasing number of clinical trials are investigating HDI in
different tumors emphasizing their potential as omnipotent anti-
cancer agents. However, as more and more non-histone proteins
are revealed as acetylated, consideration of potential effects toward
transcription factors like c-Myc (Vervoorts et al., 2003; Faiola et al.,
2005; Zhang et al., 2005), or p53 (Knights et al., 2006) have to
be considered. ES cell lines and other pediatric tumor cell lines
are relatively sensitive to HDIs (Furchert et al., 2007; Sonnemann
et al., 2007). With the number of non-histone targets for acety-
lation increasing (Choudhary et al., 2009), consideration of HDI
effects upon non-histone proteins should be investigated in terms
of overall toxicity toward tumor cells. A key caveat to our work is
our limited scope of promoter evaluation, such that future exper-
iments might find differential effects of acetylation based upon
the specific EWS-FLI1 regulated promoters (or gene expression)
that are studied. As HDI will be used in Phase II trials of ES (and
other pediatric tumors), we investigated HDI as modulators of
EWS-FLI1.
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FIGURE 7 | EWS-FLI1 acetylation increases upon HDI treatment and
co-expression of PCAF. (A) Cos 7 cells were co-transfected with EWS-FLI1
type I and PCAF-expression plasmid or empty vectors to show that
EWS-FLI1 interacts with PCAF in Cos 7 cells. Thirty hours post transfection
cells were lysed and lysate was subjected to immunoprecipitation with
α-FLI1 or IgG antibodies. Western blots were probed with α-FLI1 and
α-PCAF antibodies. (B) Cos 7 cells were transfected with wt EWS-FLI1,
with or without PCAF. Acetylated EWS-FLI1 was detected by single
site-specific antibodies K240Ac and K380Ac. (C) Cos 7 cells were
transfected with wt EWS-FLI1 or EF-K4bR constructs, with or without PCAF.
(D) Cos 7 cells were transfected using pCIneo empty vector, wt-EWS-FLI1,
or its acetylation mutant EF-K4bR in combination with pcDNA-4TO empty
vector or pcDNA4TO-PCAF and the NR0B1 reporter construct. The next day
cells were treated with SAHA (2µM) or TSA (0.3µM) for 8 h (control:
untreated) and then subjected to luciferase and western blot analysis.
Luciferase activity was expressed as luciferase activity (sample) – luciferase
activity (empty vector control) containing both empty vectors (pcDNA4TO
and pciNeo). Bar graphs result from triplicate transfection and duplicate
luciferase measurement. Two-tailed t -test was performed using GraphPad
Prism version 4.00.
Our observations of increased transcriptional and DNA bind-
ing activity seems a relative contraindication for application of
HDI for ES therapy. However, ES cells undergo apoptosis despite
(or even because of) the increased transcriptional activity of EWS-
FLI1. While the role acetylation plays in EWS-FLI1 regulation is
not yet fully evaluated, we have developed useful tools (acetylation
specific EWS-FLI1 antibodies). It would be prudent to incor-
porate more clinically relevant models to investigate a potential
clinical correlation of the EWS-FLI1 acetylation status with ther-
apy responsiveness. Thus, well-informed clinical trials with HDI
in ES should proceed cautiously based upon overall anti-tumor
effects. As with other targeted therapies, nuances of the target may
be critical to understand in order to derive the greatest clinical
benefits.
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